T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.385 NOK -0.63% Market Closed
Market Cap: 749.9m NOK
TRMED
/
Income Statement
/
Revenue

Thor Medical ASA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Thor Medical ASA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
T
Thor Medical ASA
OSE:TRMED
Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Revenue
kr257.4m
CAGR 3-Years
43%
CAGR 5-Years
31%
CAGR 10-Years
29%
B
Bergenbio ASA
OSE:BGBIO
Revenue
kr848k
CAGR 3-Years
3%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
L
Lytix Biopharma AS
OSE:LYTIX
Revenue
kr4m
CAGR 3-Years
N/A
CAGR 5-Years
64%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Revenue
kr104.4m
CAGR 3-Years
-7%
CAGR 5-Years
18%
CAGR 10-Years
12%
N
Nykode Therapeutics ASA
OSE:NYKD
Revenue
$8.7m
CAGR 3-Years
-37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Thor Medical ASA
Glance View

Market Cap
749.9m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.093 NOK
Overvaluation 96%
Intrinsic Value
Price
T
What is Intrinsic Value?

See Also

What is Thor Medical ASA's Revenue?
Revenue
0 NOK

Based on the financial report for Jun 30, 2024, Thor Medical ASA's Revenue amounts to 0 NOK.

Back to Top
ALPHA SPREAD
Follow us
Join more than 250,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.